Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 1/20 | 0.46 |
| ▸ | ATP4B | P51164 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | FABP6 | P51161 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.44 |
| ▸ | MASP2 | O00187 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.43 |
| ▸ | TUBB | P07437 | 3/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.43 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5679917 | 0.90 | FABP6 (0.47) | ATP4AATP4BS1PR4S1PR1S1PR5 | |
| SCHEMBL3500728 | 0.88 | S1PR4 (0.59) | ATP4AATP4BSKP2S1PR4S1PR1 | |
| SCHEMBL5681591 | 0.83 | TYMS (0.52) | ATP4AATP4BFABP6MASP2MEN1 | |
| SCHEMBL17702654 | 0.83 | TUBB4A (0.44) | ATP4AATP4BSKP2S1PR4S1PR1 | |
| SCHEMBL8083834 | 0.81 | TUBB4A (0.43) | ATP4AATP4BSKP2S1PR4S1PR1 | |
| SCHEMBL9295726 | 0.80 | MPL (0.57) | ATP4AATP4BTUBB4ATUBBTUBA3C | |
| SCHEMBL15156275 | 0.80 | SCN10A (0.47) | ATP4AATP4BSKP2S1PR4S1PR1 | |
| SCHEMBL20863743 | 0.79 | TUBB4A (0.41) | ATP4AATP4BSKP2S1PR4S1PR1 | |
| SCHEMBL19191488 | 0.79 | TUBB4A (0.53) | ATP4AATP4BSKP2S1PR4S1PR1 | |
| SCHEMBL15938795 | 0.78 | ALDH1A1 (0.50) | FABP6MASP2MEN1ALDH1A1NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184033-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | Lineage Cell Therapeutics, Inc. | 2010-07-22 | — | — | US | disclosed |
| US-20080226601-A1 | Herpes Virus-Based Compositions and Methods of Use in the Prenatal and Perinatal Periods | UNIVERSITY OF ROCHESTER (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | BROWN TRUMAN R | 2006-04-27 | — | — | US | disclosed |
| US-5326779-A | Method of inhibiting the advanced glycosylation of proteins using 1,2-disubstituted-benzimidazoles | THE ROCKEFELLER UNIVERSITY (US) | 1994-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | ALDOA, FBP1, GYS2 | ATP4A 2433/4885ATP4B 3294/4885SKP2 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.